General Information of This Drug (ID: DMHVEGJ)

Drug Name
CC-930   DMHVEGJ
Synonyms
TANZISERTIB; CC-930; 899805-25-5; CC 930; UNII-M5O06306UO; CHEMBL1950289; M5O06306UO; CC930; Trans-4-({9-[(3s)-Tetrahydrofuran-3-Yl]-8-[(2,4,6-Trifluorophenyl)amino]-9h-Purin-2-Yl}amino)cyclohexanol; Tanzisertib [USAN:INN]; 3tti; trans-4-((9-((3S)-Tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol; Tanzisertib (USAN); CC-930(Tanzisertib); SCHEMBL2133061; SCHEMBL4760419; SCHEMBL2133055; GTPL9836; SCHEMBL8082102; SCHEMBL15589918; CHEMBL1950305; SCHEMBL10179476; JNK-930; MolPort-044-562-358
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Idiopathic pulmonary fibrosis DISZGA69 CB03.4 Phase 2 [1]
Discoid lupus erythematosus DISMK3AH EB51.0 Phase 2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01203943) A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.